Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07594093 | Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity | PHASE1 | NOT YET_RECRUITING | 90 | — | — | Jun 15, 2026 | Feb 22, 2027 | May 18, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| REGN20934 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN20934 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1\. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2 Key Exclusion Criteria: 1. A self-reported change of body weight \>5 kg within approximately 90 days of visit 2 2. History of type 1 or type 2 diabetes 3. History of clinically significant cardiovascular, respiratory, hepati...